Watch GLSI. Know when insiders buy.
One email the day a filing lands. Free.
GLSI
Greenwich LifeSciences, Inc.
15.63
−0.46 −2.86%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · shorts 40
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $229.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$22.5MNET CASH —52W 7.85 – 33.56SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4M | −$3.9M | — | -0.27 | −$1.9M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$5.7M | −$5.7M | — | -0.39 | −$4.7M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$7.9M | −$9.2M | — | -0.67 | −$3.2M | — | — | Jun 1 |
| Q3 2025 · Sep 30 | — | — | — | −$4.2M | −$3.7M | — | -0.27 | −$2.7M | — | — | Jun 1 |
| Q2 2025 · Jun 30 | — | — | — | −$3.8M | −$3.7M | — | -0.28 | −$2.2M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$2.8M | −$2.7M | — | -0.21 | −$1.8M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$9.7M | −$9.7M | — | -0.74 | −$1.9M | — | — | Jun 1 |
| Q3 2024 · Sep 30 | — | — | — | −$2.7M | −$2.7M | — | -0.20 | −$2.6M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$2.7M | −$2.6M | — | -0.20 | −$1M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$2.5M | −$2.5M | — | -0.19 | −$1.8M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.8M | −$2.7M | — | -0.21 | −$2.2M | — | — | Apr 15 |
| Q3 2023 · Sep 30 | — | — | — | −$2.5M | −$2.4M | — | -0.19 | −$1.8M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$19.4M | −$19.4M | — | -1.43 | −$9.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$17.6M | −$17.4M | — | -1.34 | −$7.3M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$9.3M | −$8.9M | — | -0.69 | −$6.5M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$8M | −$7.8M | — | -0.61 | −$6.2M | — | — | $7.5M | — |
| FY2021 · to Dec 31 | — | — | −$4.6M | −$4.6M | — | -0.35 | −$4.3M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$1.9M | −$1.9M | — | -0.20 | −$1.2M | — | — | — | — |
Every number comes from Greenwich LifeSciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.